Arvinas, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110, proteolysis targeting chimeras (PROTAC) that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of women with metastatic ER positive/HER2 negative breast cancer. The company is also developing other PROTACs for degrading AR and other clinically relevant AR point mutations; and various other products for the treatment of neurodegenerative diseases, including tauopathies. Arvinas, Inc. was founded in 2015 and is based in New Haven, Connecticut.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone203-535-1456
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$14.32 million
Profitability
Miscellaneous
Employees83
Next Earnings Date11/4/2019 (Estimated)
OptionableNot Optionable
Arvinas (NASDAQ:ARVN) Frequently Asked Questions
What is Arvinas' stock symbol?
Arvinas trades on the NASDAQ under the ticker symbol "ARVN."
How were Arvinas' earnings last quarter?
Arvinas Inc (NASDAQ:ARVN) announced its earnings results on Monday, August, 5th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.40) by $0.15. The firm earned $4.02 million during the quarter, compared to analysts' expectations of $4 million. Arvinas had a negative net margin of 411.20% and a negative return on equity of 239.20%. View Arvinas' Earnings History.
When is Arvinas' next earnings date?
What price target have analysts set for ARVN?
7 analysts have issued 12 month price objectives for Arvinas' shares. Their predictions range from $17.00 to $42.00. On average, they anticipate Arvinas' share price to reach $30.83 in the next twelve months. This suggests a possible upside of 100.3% from the stock's current price. View Analyst Price Targets for Arvinas.
What is the consensus analysts' recommendation for Arvinas?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arvinas.
Has Arvinas been receiving favorable news coverage?
News headlines about ARVN stock have trended somewhat negative recently, according to InfoTrie Sentiment. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Arvinas earned a news impact score of -1.5 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Arvinas.
Are investors shorting Arvinas?
Arvinas saw a increase in short interest in September. As of September 30th, there was short interest totalling 707,100 shares, an increase of 6.4% from the August 30th total of 664,600 shares. Based on an average daily volume of 167,500 shares, the days-to-cover ratio is currently 4.2 days. Currently, 4.4% of the shares of the stock are short sold. View Arvinas' Current Options Chain.
Who are some of Arvinas' key competitors?
Some companies that are related to Arvinas include PTC Therapeutics (PTCT), Ra Pharmaceuticals (RARX), BridgeBio Pharma (BBIO), Intercept Pharmaceuticals (ICPT), Amicus Therapeutics (FOLD), Xencor (XNCR), Ligand Pharmaceuticals (LGND), Cambrex (CBM), Zai Lab (ZLAB), Agios Pharmaceuticals (AGIO), Zogenix (ZGNX), Akcea Therapeutics (AKCA), Portola Pharmaceuticals (PTLA), Prestige Consumer Healthcare (PBH) and Deciphera Pharmaceuticals (DCPH).
What other stocks do shareholders of Arvinas own?
Who are Arvinas' key executives?
Arvinas' management team includes the folowing people:
- Dr. John G. Houston Ph.D., CEO, Pres & Director (Age 59)
- Mr. Sean A. Cassidy, CFO & Treasurer (Age 49)
- Dr. Ian Taylor, Chief Scientific Officer (Age 56)
- Dr. Craig M. Crews, Founder, Chief Scientific Advisor & Member of Scientific Advisory Board
- Dr. Andrew Crew, Chief Technology Officer (Age 54)
When did Arvinas IPO?
(ARVN) raised $100 million in an initial public offering (IPO) on Thursday, September 27th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray acted as the underwriters for the IPO.
How do I buy shares of Arvinas?
Shares of ARVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Arvinas' stock price today?
One share of ARVN stock can currently be purchased for approximately $15.39.
How big of a company is Arvinas?
Arvinas has a market capitalization of $518.55 million and generates $14.32 million in revenue each year. The company earns $-41,480,000.00 in net income (profit) each year or ($25.45) on an earnings per share basis. Arvinas employs 83 workers across the globe.View Additional Information About Arvinas.
What is Arvinas' official website?
How can I contact Arvinas?
Arvinas' mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The company can be reached via phone at 203-535-1456 or via email at [email protected]
MarketBeat Community Rating for Arvinas (NASDAQ ARVN)
MarketBeat's community ratings are surveys of what our community members think about Arvinas and other stocks. Vote "Outperform" if you believe ARVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARVN will underperform the S&P 500 over the long term. You may vote once every thirty days.
